Results 211 to 220 of about 3,807,237 (401)

METTL3 knockout accelerates hepatocarcinogenesis via inhibiting endoplasmic reticulum stress response

open access: yesFEBS Open Bio, EarlyView.
Liver‐specific knockout of N6‐methyladenosine (m6A) methyltransferase METTL3 significantly accelerated hepatic tumor initiation under various oncogenic challenges, contrary to the previously reported oncogenic role of METTL3 in liver cancer cell lines or xenograft models. Mechanistically, METTL3 deficiency reduced m6A deposition on Manf transcripts and
Bo Cui   +15 more
wiley   +1 more source

Integrative Transformation System for the Metabolic Engineering of the Sphingoid Base-Producing Yeast Pichia ciferrii [PDF]

open access: green, 2003
Jung‐Hoon Bae   +4 more
openalex   +1 more source

Adenosine A3 receptor antagonists as anti‐tumor treatment in human prostate cancer: an in vitro study

open access: yesFEBS Open Bio, EarlyView.
The A3 adenosine receptors (A3ARs) are overexpressed in prostate cancer. AR 292 and AR 357, as A3AR antagonists, are capable of blocking proliferation, modulating the expression of drug transporter genes involved in chemoresistance, ferroptosis, and the hypoxia response, and inducing cell death.
Maria Beatrice Morelli   +15 more
wiley   +1 more source

Induction of male sterility in plants by metabolic engineering of the carbohydrate supply

open access: green, 2001
Marc Goetz   +5 more
openalex   +1 more source

Downregulation of O‐GlcNAcylation enhances etoposide‐induced p53‐mediated apoptosis in HepG2 human liver cancer cells

open access: yesFEBS Open Bio, EarlyView.
Etoposide, a topoisomerase II inhibitor, reduces O‐GlcNAcylation in HepG2 liver cancer cells. Further inhibition of O‐GlcNAc transferase by OSMI‐1 enhanced etoposide‐induced apoptosis, lowering the IC50 for viability and increasing the EC50 for cytotoxicity.
Jaehoon Lee   +5 more
wiley   +1 more source

Metabolic engineering: Tools and applications

open access: yesEngineering Microbiology, 2023
Yun Chen, Jiazhang Lian, Jin Hou
doaj  

Long non‐coding RNAs as therapeutic targets in head and neck squamous cell carcinoma and clinical application

open access: yesFEBS Open Bio, EarlyView.
Long non‐coding RNAs (lncRNAs) occupy an abundant fraction of the eukaryotic transcriptome and an emerging area in cancer research. Regulation by lncRNAs is based on their subcellular localization in HNSCC. This cartoon shows the various functions of lncRNAs in HNSCC discussed in this review.
Ellen T. Tran   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy